Literature DB >> 29528042

Does Late Gadolinium Enhancement still have Value? Right Ventricular Internal Mechanical Work, Ea/Emax and Late Gadolinium Enhancement as Prognostic Markers in Patients with Advanced Pulmonary Hypertension via Cardiac MRI.

Amr Ei Abouelnour1, Mark Doyle1, Diane V Thompson1, June Yamrozik1, Ronald B Williams1, Moneal B Shah1, Siva Kr Soma1, Srinivas Murali1, Raymond L Benza1, Robert Ww Biederman1.   

Abstract

OBJECTIVES: Investigate the impact of Right Ventricular (RV) Internal Work (IW), ratio of arterial to ventricular end-systolic elastance (Ea/Emax), and RV Insertion Point (IP) Late Gadolinium Enhancement (LGE) on outcome in Pulmonary Hypertension (PH) patients.
BACKGROUND: LGE is well known to be present within the RVIPs and Inter Ventricular Septum (IVS) in PH patients, but its prognostic role remains complex and potentially overestimated via 2D qualitative relative to the 3D quantitative measures now available. However, Ea/Emax, a measure of ventricular-arterial coupling and IW, when added to external cardiac work i.e. the P-V loop area as correlates to the heart's energy demands, might fundamentally improve measures of prognosis as they interrogate physiology beyond just the RV.
METHODS: Cardiac Magnetic Resonance Imaging (CMR) of 124 PH patients (age = 60±13, 85F) referred to a large tertiary PH center, was retrospectively examined for RV volumetric and functional indices and RVIP LGE%. Right Heart Catheterizations (RHC) performed within 1±2 months of the CMR were reviewed. Ea/Emax was derived as RV End-Systolic Volume (ESV/RVSV). IW was estimated as RVESV ×(RV end-systolic pressure-RV diastolic pressure). Patients were followed from date of CMR for up to 5 years for MACE (death, hospitalized RV failure, initiation of parenteral prostacyclin, sustained ventricular arrhythmia or referral for lung transplantation).
RESULTS: MACE was high; 48/124 (39%) patients had MACE by 1.6±1.3 years. Neither RVIP nor IVS LGE using visual assessment or even 3D quantization predicted MACE. The strongest predictor of MACE was RVIW (OR=1.00013, p<0.002), vs. mPAP, RV mass, RV EF and IP LGE.
CONCLUSIONS: Surprisingly, neither a single time-point RVIP nor whole IVS LGE% can predict outcome in the largest cohort of PH patients studied to date when compared with conventional or contemporary metrics of disease progression. CMR-LGE appears to lose its' prognostic value in PH patients in stark contradistinction to all other left and right-sided human myocardial pathologies.

Entities:  

Keywords:  CMR; Cardiac MRI; Insertion Point LGE; Internal Mechanical Work; Prognosis; Pulmonary Hypertension; Ventriculoarterial Coupling

Year:  2017        PMID: 29528042      PMCID: PMC5843365     

Source DB:  PubMed          Journal:  Cardiol Res Cardiovasc Med        ISSN: 2575-7083


  40 in total

1.  Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension.

Authors:  Serge A van Wolferen; Johannes T Marcus; Anco Boonstra; Koen M J Marques; Jean G F Bronzwaer; Marieke D Spreeuwenberg; Pieter E Postmus; Anton Vonk-Noordegraaf
Journal:  Eur Heart J       Date:  2007-01-22       Impact factor: 29.983

2.  LV reverse remodeling imparted by aortic valve replacement for severe aortic stenosis; is it durable? A cardiovascular MRI study sponsored by the American Heart Association.

Authors:  Robert W W Biederman; James A Magovern; Saundra B Grant; Ronald B Williams; June A Yamrozik; Diane A Vido; Vikas K Rathi; Geetha Rayarao; Ketheswaram Caruppannan; Mark Doyle
Journal:  J Cardiothorac Surg       Date:  2011-04-14       Impact factor: 1.637

3.  Prevalence and correlates of septal delayed contrast enhancement in patients with pulmonary hypertension.

Authors:  Javier Sanz; Santo Dellegrottaglie; Mbabazi Kariisa; Roxana Sulica; Michael Poon; Thomas P O'Donnell; Davendra Mehta; Valentin Fuster; Sanjay Rajagopalan
Journal:  Am J Cardiol       Date:  2007-06-27       Impact factor: 2.778

Review 4.  Monitoring tissue repair and fibrosis from a distance.

Authors:  K T Weber
Journal:  Circulation       Date:  1997-10-21       Impact factor: 29.690

5.  Analysis of myocardial mucopolysaccharides in hyper-and hypothyroid rats and guinea-pigs.

Authors:  J Von Knorring
Journal:  Ann Med Exp Biol Fenn       Date:  1970

6.  Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy.

Authors:  Mariëlle C van de Veerdonk; Taco Kind; J Tim Marcus; Gert-Jan Mauritz; Martijn W Heymans; Harm-Jan Bogaard; Anco Boonstra; Koen M J Marques; Nico Westerhof; Anton Vonk-Noordegraaf
Journal:  J Am Coll Cardiol       Date:  2011-12-06       Impact factor: 24.094

7.  Cardiac magnetic resonance-derived right ventricular outflow tract systolic flow acceleration: a novel index of right ventricular function and prognosis in patients with pulmonary arterial hypertension.

Authors:  Ki-Woon Kang; Hyuk-Jae Chang; Yeon Pyo Yoo; Hyeon Soo Yoon; Young-Jin Kim; Byoung-Wook Choi; Chi-Young Shim; Jongwon Ha; Namsik Chung
Journal:  Int J Cardiovasc Imaging       Date:  2013-07-17       Impact factor: 2.357

Review 8.  Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system.

Authors:  K T Weber; C G Brilla
Journal:  Circulation       Date:  1991-06       Impact factor: 29.690

9.  Contractile state of the left ventricle in man as evaluated from end-systolic pressure-volume relations.

Authors:  W Grossman; E Braunwald; T Mann; L P McLaurin; L H Green
Journal:  Circulation       Date:  1977-11       Impact factor: 29.690

10.  Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension.

Authors:  Benjamin H Freed; Mardi Gomberg-Maitland; Sonal Chandra; Victor Mor-Avi; Stuart Rich; Stephen L Archer; E Bruce Jamison; Roberto M Lang; Amit R Patel
Journal:  J Cardiovasc Magn Reson       Date:  2012-02-01       Impact factor: 5.364

View more
  5 in total

Review 1.  Evaluation and classification of pulmonary arterial hypertension.

Authors:  Sandeep Sahay
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

Review 2.  Novel Approaches to Imaging the Pulmonary Vasculature and Right Heart.

Authors:  Fawaz Alenezi; Taylor A Covington; Monica Mukherjee; Stephen C Mathai; Paul B Yu; Sudarshan Rajagopal
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

3.  Diagnosis of pulmonary hypertension.

Authors:  Adaani Frost; David Badesch; J Simon R Gibbs; Deepa Gopalan; Dinesh Khanna; Alessandra Manes; Ronald Oudiz; Toru Satoh; Fernando Torres; Adam Torbicki
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

4.  EXPRESS: Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI).

Authors:  David G Kiely; David Levin; Paul Hassoun; David D Ivy; Pei-Ni Jone; Jumaa Bwika; Steven M Kawut; Jim Lordan; Angela Lungu; Jeremy Mazurek; Shahin Moledina; Horst Olschewski; Andrew Peacock; Goverdhan Dutt Puri; Farbod Rahaghi; Michal Schafer; Mark Schiebler; Nicholas Screaton; Merryn Tawhai; Edwin Jr Van Beek; Anton Vonk-Noordegraaf; Rebecca R Vanderpool; John Wort; Lan Zhao; Jim Wild; Jens Vogel-Claussen; Andrew J Swift
Journal:  Pulm Circ       Date:  2019-03-18       Impact factor: 3.017

Review 5.  Cardiac Magnetic Resonance in Pulmonary Hypertension-an Update.

Authors:  Samer Alabed; Pankaj Garg; Christopher S Johns; Faisal Alandejani; Yousef Shahin; Krit Dwivedi; Hamza Zafar; James M Wild; David G Kiely; Andrew J Swift
Journal:  Curr Cardiovasc Imaging Rep       Date:  2020-11-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.